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Objective. The objective of the present study is to investigate the eﬀect of rosiglitazone, metformin, ezetimibe, and valsartan (alone
or in combinations) on paraoxonase (PON) activity and PON-mRNA expression in nonalcoholic fatty liver disease (NAFLD).
Methods. 54 Male Sprague–Dawley rats were divided to 9 groups: chow diet group (15 weeks); methionine-choline-deﬁcient diet
(MCDD) group (15 weeks); MCDD-treated groups for the last 6 weeks with either metformin (M), rosiglitazone (R), metformin
plus rosiglitazone (M+R), ezetimibe (E), valsartan (V), or a combination of R+M+V or of R+M+V+E for a total period of 15
weeks. Results. PON activities in serum and liver were decreased in MCDD rats. PON activity in serum increased signiﬁcantly in
all treatment groups. PON activity in liver was also increased signiﬁcantly, except only in groups R, E, V, R+M+V, and R+M+V+E.
Liver PON3 mRNA expression increased signiﬁcantly in groups R+M, E, V, R+M+V, and R+M+V+E whereas liver PON2 mRNA
expression increased signiﬁcantly in MCDD, R+M, E, V, R+M+V, and R+M+V+E. Conclusions. PON activities in serum and
liver were decreased in NAFLD. Treatment with insulin sensitizers, ezetimibe, and valsartan increased PON activity and reduced
oxidative stress both in serum and liver.
1.Background
Paraoxonase (PON) aryldialkylphosphatase is an ester
hydrolase that catalyzes the hydrolysis of some xenobiotics,
such as organophosphates, unsaturated aliphatic esters,
aromatic carboxylic esters and, possibly, carbamates [1]. The
paraoxonase gene family contains at least three members,
PON1,PON2,andPON3,whicharelocatedonchromosome
7q21.3–22.1 [2–4]. PON1 and PON3 mRNA are predomi-
nantly expressed in liver, whereas PON2 mRNA is found in
diﬀerent tissues [5] including human endothelial and aortic
smooth muscle cells [6]. The enzymes PON1 and PON3 are
circulating in serum and tightly bound with HDL in serum,
and several studies suggest that it is this association that
contributes to the protection conferred by HDL against LDL
oxidation[7,8].PON2iscellassociatedandisnotcirculating
in the serum [6]. PON2 has been shown to reduce reactive
oxygen species (ROS) in HeLa cells, reverse the oxidation
of oxidized low-density lipoprotein, and inhibit the ability
of oxidized low-density lipoprotein to induce monocyte
chemotaxis [6], which can contribute to its antiatherogenic
properties.
Serum PON1 is synthesized mainly in the liver. The
gene expression has been observed only in the liver [9, 10].
Arylesterase and PON1 activities have been shown to be2 International Journal of Hepatology
functions of a single enzyme [11]. Lipid peroxidation
products are increased [12, 13] and levels of endogenous
antioxidantsaredecreasedinpatientswithnonalcoholicliver
disease (NAFLD) [14]. Chronic exposure to increased levels
of oxidative stress may result in an excess of ROS within
the hepatocytes which can contribute to the deterioration
from NAFLD to non-alcoholic steatohepatitis (NASH).
Liver antioxidant enzyme activities Cu/Zn-superoxide
dismutase (SOD), glutathione peroxidase (GSHPx), and
catalase were high in patients with NAFLD, but with normal
thiobarbituric acid-reactive substance, which is a measure
of the oxidative end product malonyl aldehyde (MDA) level
[15]. Thus, in NAFLD, the increased antioxidant enzymes
activities contained the oxidative stress and prevented the
increment in MDA levels. Serum nitric oxide, SOD, GSHPx
and PON1 activities [16], CuZn-SOD and catalase activities
[17],andthiollevels[16,18]werelowinpatientswithNASH
and incapable to compensate for oxidative stress. Increased
lipid peroxidation and ROS in NAFLD consume antioxidant
vitamins and can inactivate PON [19]. Decreased anti-
oxidative defense may increase hepatocyte susceptibility to
injury leading to aggravate NAFLD to NASH.
Decreased serum PON1 activity in NASH patients can be
secondary to increased levels of proinﬂammatory cytokines
such as interleukin-1 and TNF-α which downregulated
mRNA expression of PON1 in HepG2 cells [20]. Decrease in
liver microsomal PON1 activity is related to lipid peroxida-
tionandliverinjuryinratswithCCl4-inducedcirrhosis[21].
Decreased PON1 activity in sera of patients with chronic
liver disease was suggested to be related to the degree of
liver damage and not to allelic or genotypic diﬀerences [22].
On the contrary, in a recent study, there was no statistically
signiﬁcant correlation between degree of liver damage(grade
andstageofNASH)fromonesideandbetweenserumPON1
and MDA levels from the other side [23]. PON activity
decreased signiﬁcantly in the livers of Sprague-Dawley rats
with experimental NAFLD induced by MCDD alone or
enriched with olive oil, butter fat, or ﬁsh oil. The most
prominent decrease in paraoxonase activity of 67.8% was
observed in rats on MCDD enriched with olive oil [24]. The
oxidative stress in the liver of this group was also higher
than other groups on MCDD. As was previously reported
by our group, MCDD rat group increased signiﬁcantly the
liver weight/rat weight ratio by 68%, hepatic triglyceride
content by 1263%, and hepatic cholesterol content by 245%
comparedwiththegrouponchowdiet.Inthegrouponchow
diet(thecontrolgroup),theseparameterswere0.025±0.003,
1.6±0.3mol/g,and0.5±0.0mol/g,respectively .TheMCDD
group showed massive fatty inﬁltration, predominantly
macrovesicular.Therewasmildballooningdegenerationand
pericellular ﬁbrosis [25]. Liver weight/body weight ratio in
MCDD groups related to the ratio in chow group, liver,
and serum triglyceride and cholesterol levels, serum alanine
transaminase, fat inﬁltration in the liver and features of
steatohepatitis were reported previously [25].
The keyobjectives of the present study are to investigate
theeﬀectofinsulinsensitizers(rosiglitazoneandmetformin),
ezetimibe, and valsartan (each alone or in combinations) on
plasmaPONactivityandPON-mRNAexpressionintheliver
and the potential protective role in NAFLD. To explain the
paradox of increased oxidative stress with decreased PON
activity in the MCDD rat group, we conducted this study.
2.AnimalandProtocol
Male Sprague-Dawley rats (Harlan Laboratories Limited;
Jerusalem, Israel) weighting 200–280 grams were studied.
Ratswerehousedinregularcagessituatedinananimalroom
at 22◦C. The rats before the beginning of the study were
maintained on standard rat chow diet (Koﬀolk, Tel Aviv,
Israel) and were given tap water to drink ad libitum. All
animal studies were conducted according to the regulations
for the use and care of experimental animals and treatment
groups. The researchers were authorized to conduct the
experiments after a formal training. The experiments were
done in an authorized animal housing and laboratory
systems.
Fatty liver was induced in rats fed by methionine-
choline-deﬁcient diet (MCDD TD.90262, Harlan Teklad,
MadisonWI) for 9 weeks [26]. The constituents of MCDD
as percent by weight were protein 14.9, carbohydrate 64.3,
and fat 10.0. The rats were randomly divided to nine
groups, 6 rats in each group. Group 1 served as control
group and was maintained on standard chow diet for 15
weeks (control). Group 2 (MCDD group) was given only
MCDD for 15 weeks. The following groups (3–9) were on
MCDD but were treated during weeks 9–15 with various
pharmaceutical interventions. Group 3 was fed MCDD
with rosiglitazone (3mg/kg), Group 4 was fed MCDD with
metformin (200mg/kg), Group 5 was fed MCDD with
metformin + rosiglitazone, Group 6 was fed MCDD with
ezetimibe (2mg/kg), Group 7 was fed MCDD with valsartan
(2mg/kg), Group 8 was fed MCDD with metformin +
rosiglitazone + valsartan, and Group 9 was fed MCDD with
metformin + rosiglitazone + valsartan + ezetimibe. The
dosagewasselectedforeachinterventionbasedontheresults
ofpreviousstudiesusingtheseagentsinvariousliverdiseases
[27–30].Thedosageofthedrugsinthecombinedtreatments
was the same as that in the groups treated with a single agent
to maximize the combined eﬀect. The standard rat chow diet
contains 21.9% protein, 4.5% fat, 41% starch, 5% sugar, and
3.7% crude ﬁbers. Diets were supplied in pellets form. The
medications were given with food and in drinking water.
All the drugs are water soluble and there was no need for
additional solvents. The drugs were monitored daily and the
formula was prepared and supplied by the local pharmacy
of the Ziv Medical Center, Safed, Israel and not by pharma-
ceutical companies. The companies that produced the drugs
wereGlaxoSmithKline (rosiglitazone), Dexxon (metformin),
MSD (ezetimibe), and Novartis (valsartan). The animals
were kept at 37◦C for 30 minutes before measurements,
that were reported in previous publication, [25] were taken.
Blood samples were taken by cardiac puncture. Rats were
then sacriﬁced and liver and plasma were examined.
Malondialdehyde (MDA) levels were analyzed by the
thiobarbituric acid reactive substancesassay, which measures
malondialdehyde equivalent [31].International Journal of Hepatology 3
Serum paraoxonase activity was determined by an adap-
tation of the spectrophotometric method of Furlong et al.
[32]. Aliquots (10μL) of diluted (1:5) serum were placed in
microliter plate wells in triplicate; the reaction was initiated
by adding 190μL of the substrate (1.2mmol/L paraoxon
in 0.26mmol/LTris-HCL, pH 8.5, 25mmol/L CaCl2, and
0.5mol/L Nacl). After mixing, the plate was read imme-
diately at 450nm to establish zero time values. Readings
were repeated at 2min interval for 10min. Nonenzymatic
hydrolysis of paraoxon was subtracted from the total rate
of hydrolysis. The enzyme activity was calculated from the
linear portion of the plot using the molar extinction for
p-nitrophenol (17,100mol/L). One unit of paraoxonase1
activity equals 1μmol/L·min of released p-nitrophenol.
PON arylesterase activity was measured by using pheny-
lacetate as substrate. Nonenzymatic hydrolysis of pheny-
lacetate was not observed. The reaction took place in
Tris buﬀer (50mM Tris-HCl, pH 8, 1mM CaCl2)a n d
was initiated by adding the substrate. Absorbance (λ =
270nm) was measured at zero time and after 2min. The
enzymatic activity is expressed as micromoles of hydrolyzed
phenylacetate.min−1·mL−1 (U/mL) or per mg of liver tissue
[33].
Liver PON2 and PON3 mRNA expression by semiquan-
titative reverse transcriptase-polymerase chain reaction (RT-
PCR): total RNA from rat livers was extracted with Tri-
reagent (Sigma-Aldrich, Israel). cDNA was generated from
5μg of total RNA using 0.5μg random primers (Sigma-
Genosys, Israel). Reverse transcriptase products were sub-
jectedtoPCRampliﬁcationwithReadyMixPCRMasterMix
(ABgene, Epsom, Surrey, UK). The ampliﬁcation conditions
were denaturation at 94◦C for 15s, annealing at 57◦Cf o r
20s, and extension at 70◦C for 15s during 30 cycles for
PON2 and PON3 [34] .T h ec D N Ap r o d u c t sw e r es e p a r a t e d
on2%agarosegelwithethidiumbromide.Densitometrywas
performed using Tina 2.0g software (Fujiﬁlm, Stockholm,
Sweden).
3.StatisticalAnalysis
Results were expressed as mean ± standard deviation.
ANOVA Tukey’s post hoc test was used to examine diﬀerences
between means. P<0.05 was considered signiﬁcant.
4. Results
Rats on MCDD for 9 weeks showed increased MDA levels in
serum and liver by 264% (P<0.01) and 124% (P<0.01),
respectively (Figure 1, Table 1). PON activities in serum and
liver were decreased by 43% (P<0.05) and 44% (P<
0.01), respectively (Figures 2(a) and 2(b)). In the liver, PON3
mRNA expression was not changed, while PON2 mRNA
expression increased by 113% (P<0.05) (Figures 2 and 3,
Table 1).
Treatment with rosiglitazone in comparison with rats on
MCDD did not aﬀect serum MDA level, while liver MDA
level was lowered by 36% (P<0.01), which was not signi-
ﬁcantly diﬀerent from control group (Figure 1). Serum PON
activity increased under rosiglitazone therapy by 43% (P<
0.01) in comparison with control group and by 148% in
comparison with MCDD group (P<0.01). Liver PON
activity decreased by 68% (P<0.01) under rosiglitazone
treatment in comparison with control group but was not
diﬀerent in comparison with MCDD group (Figure 2).
PON2 mRNA expression decreased by 55% (P<0.01)
undertreatmentbyrosiglitazoneincomparisonwithMCDD
group, back to the level of control group. PON3 mRNA
expression was not signiﬁcantly diﬀerent in comparison with
the control and MCDD groups (Figures 2 and 3).
I nr a t st r e a t e dw i t hm e t f o r m i n ,M D Al e v e l si ns e r u m
and liver were decreased by 37% (P<0.01) and 58.3%
(P<0.01), respectively, in comparison with MCDD group.
Metformin normalized MDA level in the liver, while the
level in plasma was still 2.25-fold higher than in control
group (P<0.01) (Figure 1). Metformin treatment increased
serum PON activity by 134% (P<0.01) in comparison
to MCDD group to the normal activity in control group.
Metformin did not aﬀect the decreased liver PON activity
in comparison with MCDD group. PON2 mRNA expression
decreased by 55% (P<0.01) under treatment by metformin
in comparison with MCDD group, back to the level of
controlgroup.PON3mRNAexpressionwasnotsigniﬁcantly
diﬀerent in comparison with the control and MCDD groups
(Figures 2 and 3).
Combined treatment with rosiglitazone and metformin
in comparison with rats on MCDD decreased serum and
liver MDA levels by 39% (P<0.01) and 52% (P<0.01),
respectively. Under this treatment, plasma MDA level was
still higher than control group by 120% (P<0.01) and
liverMDAwasnotdiﬀerentfromcontrolgroup.SerumPON
activity increased by the combination of rosiglitazone and
metformin by 126% (P<0.01) in comparison with MCDD
group and was not diﬀerent from the control group. Liver
PON activity decreased by 47% (P<0.0001) and by 71%
(P<0.01) in comparison with MCDD and control groups,
respectively. PON2 mRNA expression in the liver was not
diﬀerent from that in MCDD group but 120% (P<0.01)
above that in the control group. PON3 mRNA expression
increased in the liver by 118% (P<0.01) and by 190%
(P<0.01) in comparison with the MCDD and control
groups, respectively (Figures 2 and 3).
Treatments with ezetimibe, valsartan, combined treat-
ment with rosiglitazone-metformin-valsartan, and com-
bined treatment with rosiglitazone-metformin-valsartan-
ezetimibe decreased serum MDA levels by 27% (P<0.01),
31% (P<0.01), 43% (P<0.01), and 42% (P<0.01),
respectively. None of these treatments normalized plasma
MDA levels in comparison with the control group. The same
treatments decreased liver MDA levels in comparison with
the MCDD group by 41% (P<0.01), 35% (P<0.01), 57%
(P<0.01), and 65% (P<0.01), respectively. All these treat-
ments normalized liver MDA levels in comparison with the
control group. Plasma PON activity increased signiﬁcantly
(P<0.01) by 100%, 119%, 91%, and 110% under treat-
ments with ezetimibe, valsartan, combined treatment with
rosiglitazone-metformin-valsartan,andcombinedtreatment4 International Journal of Hepatology
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Figure 1: Malondialdehyde (MDA) in sera (a) and livers (b) in rat experimental fatty liver model. Fatty liver in Sprague-Dawley rats was
induced by methionine-choline-deﬁcient diet (MCDD) for 9 weeks. Rats were treated for other 6 weeks with rosiglitazone (R); metformin
(M); rosiglitazone + metformin combination (R+M); ezetimibe (E); valsartan (V); rosiglitazone + metformin + valsartan in combination
(R+M+V), or rosiglitazone + metformin + valsartan + ezetimibe (R+M+V+E). “#” indicates P<0.05 versus control group (fed by standard
rat chow). “∗” indicates P<0.05 versus MCDD group.
Table 1: Results of serum versus liver in rat experimental fatty liver model. Fatty liver in Sprague-Dawley rats was induced by methionine-
choline-deﬁcient diet (MCDD) for 9 weeks. Rats were treated for other 6 weeks with rosiglitazone (R); metformin (M); rosiglitazone +
metformin combination (R+M); ezetimibe (E); valsartan (V); rosiglitazone + metformin + valsartan in combination (R+M+V) or rosigli-
tazone + metformin + valsartan + ezetimibe (R+M+V+E). Malondialdehyde (MDA), Paraoxonase (PON).
Change by % Serum MDA Serum PON
activity Liver MDA Liver PON
activity
Liver PON2
mRNA
Liver PON3
mRNA
MCDD Versus control +264 P<0.01 −43 P<0.05 +124 P<0.01 −44 P<0.01 +113 P<0.05 +33 P = NS
Versus MCDD
R Versus control +203 P<0.01 +43 P = 0.01 +42 P = NS −68 P<0.01 −4 P = NS −7 P = NS
Versus MCDD −15 P = NS +148 P<0.01 −37 P<0.01 −40 P = NS −55 P<0.01 −30 P = NS
M Versus control +126 P<0.01 +35 P = NS −7 P = NS −67 P<0.01 +1 P = NS +18 P = NS
Versus MCDD −37 P<0.01 +134 P<0.01 −58 P<0.01 −39 P = NS −53 P<0.01 −11 P = NS
R+M Versus control +120 P<0.01 +30 P = NS +7 P = NS −71 P<0.01 +120 P<0.01 +190 P<0.01
Versus MCDD −39 P<0.01 +126 P<0.01 −52 P<0.01 −47 P<0.01 +3 P = NS +118 P<0.01
E Versus control +162 P<0.01 +15 P = NS +32 P = NS −31 P<0.01 +174 P<0.01 +281 P<0.01
Versus MCDD −27 P<0.01 +100 P<0.01 −41 P<0.01 +28 P = NS +29 P = 0.048 +188 P<0.01
V Versus control +148 P<0.01 +26 P = NS +45 P = NS −27 P<0.05 +212 P<0.01 +452 P<0.01
Versus MCDD −31 P<0.05 +119 P<0.01 −35 P<0.01 +35 P = NS +47 P<0.05 +316 P<0.01
R+M+V Versus control +105 P<0.01 +10 P = NS −4 P = NS −40 P<0.01 +227 P<0.01 +560 P<0.01
Versus MCDD −43 P<0.01 +91 P<0.01 −57 P<0.01 +12.5 P = NS +54 P<0.01 +397 P<0.01
R+M+V+E Versus control +109 P<0.01 +21 P = NS −22 P = NS −11 P = NS +126 P<0.01 +221 P<0.01
Versus MCDD −42 P<0.01 +110 P<0.01 −65 P<0.01 +66 P<0.01 +6 P = NS +142 P<0.01
with rosiglitazone-metformin-valsartan-ezetimibe, respec-
tively. All these treatments normalized plasma PON activity
towardsthecontrolgroup.LiverPONactivitydidnotchange
under treatments with ezetimibe, valsartan, or combined
treatment with rosiglitazone-metformin-valsartan in com-
parison with MCDD group and was still signiﬁcantly lower
than the activity in control group. Combined treatment
with rosiglitazone-metformin-valsartan-ezetimibe increased
liver PON activity by 66% in comparison with MCDD
group (P<0.05) which was not signiﬁcantly diﬀerent
from control group. PON2 mRNA expression in the liver
under treatment with ezetimibe or combined treatment
with rosiglitazone-metformin-valsartan-ezetimibe was not
signiﬁcantly diﬀerent in comparison with MCDD group.
When compared with the control group, it was increased by
174% (P<0.01) in the ezetimibe group, by 212% (P<0.01)
in the valsartan group, by 227% (P<0.01) in the combined
treatment with rosiglitazone-metformin-valsartan, and by
126% (P = 0.01) in the rosiglitazone-metformin-valsartan-
ezetimibe group.International Journal of Hepatology 5
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Figure 2: Paraoxonase (PON) activity in sera (a) and livers (b); PON2 (c) and PON3 (d) mRNA expression in rat experimental fatty liver
model.FattyliverinSprague-Dawleyratswasinducedbymethionine-cholinedeﬁcientdiet(MCDD)for9weeks.Ratsweretreatedforother
6weekswithrosiglitazone(R);metformin(M);rosiglitazone+metformincombination(R+M);ezetimibe(E);valsartan(V);rosiglitazone+
metformin + valsartan in combination (R+M+V) or rosiglitazone + metformin + valsartan + ezetimibe (R+M+V+E).“#” indicates P<0.05
versus control group (fed by standard rat chow). “∗” indicates P<0.05 versus MCDD group.
PON3 mRNA expression increased signiﬁcantly (P<
0.001) in the groups ezetimibe, valsartan, rosiglitazone-met-
formin-valsartan, and rosiglitazone-metformin-valsartan-
ezetimibe by 188%, 316%, 397%, and 142% in com-
parison with MCDD group and by 282%, 452%, 560%,
and 221% in comparison with control group, respectively
(Figures 2 and 3).
5. Discussion
As was shown in previous report, there was an increased
oxidative stress in the serum and liver of MCDD rat group
(experimental NAFLD) [25] .I nt h ep r e s e n ts t u d y ,i tw a s
demonstrated that this is accompanied by decreased PON
activity in the serum and liver. In the liver of MCDD
rat group, PON3mRNA expression did not increase, while
PON2 mRNA expression increased without increased mea-
sured enzyme activity. This may be due to oxidative inacti-
vation of the PON2 protein. For PON1 it was shown that
oxidative stress in several systems can inactivate the protein
[19]. Hydroxyl radicals may be active species primarily
responsible for the oxidative inactivation of PON1 in in vivo
system [19]. Oxidized lipids were shown to inactivate both
serum and hepatic PON1 [35, 36]. Free sulfhydryl groups of
PON1interactwithspeciﬁcoxidizedlipidsandbythatPON1
is inactivated. Xanthine oxidase (XO) produces superoxide
anionswhichmaydecreasePON1activity.SerumXOactivity
was negatively correlated with PON activity [35]. In parallel,
in mouse peritoneal macrophages (MPMs), oxidative stress
markedly increased PON2 mRNA levels but had no eﬀect
on PON3 mRNA levels. When MPM lipid peroxides content
was increased, PON2 mRNA levels were signiﬁcantly higher
whereas PON3 mRNA levels were similar compared with
control cells [34]. Ex vivo as well as in vitro studies, showed
that under oxidative stress PON2 expression and enzymatic
activity increased, whereas PON3 expression did not change,
while its activity decreased [34]. In the present study,
the increased hepatic oxidative stress was associated with
increased hepatic PON2 mRNA expression, in accordance
with an other study [34]. Despite that, the hepatic PON26 International Journal of Hepatology
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Figure 3: PON2 and PON3 mRNA expression in rat fatty liver
experimentalmodel.FattyliverinSprague-Dawleyratswasinduced
by methionine-choline-deﬁcient diet (MCDD) for 9 weeks. Rats
were treated for other 6 weeks with rosiglitazone (R); metformin
(M); rosiglitazone + metformin in combination (R+M); ezetimibe
(E); valsartan (V); rosiglitazone + metformin + valsartan in
combination (R+M+V) or rosiglitazone + metformin + valsartan
+ ezetimibe (R+M+V+E). 18s ribosomal RNA was used for relative
quantiﬁcation. “#” indicates P<0.05 versus control group (fed by
standard rat chow). “∗” indicates P<0.05 versus MCDD group.
activity was decreased, possibly due to oxidative inactivation
of the protein.
Oxidative stress is mediated by several oxidants which
act by diﬀerent mechanisms. So the next step was to
examine the possibility whether polypharmacy therapy with
diﬀerent antioxidative mechanisms can have more potent
eﬀect to decrease the oxidative stress in NAFLD, and by
that to increase the enzymatic activity of hepatic PON2.
Treatments with rosiglitazone, metformin, rosiglitazone-
metformin, ezetimibe, valsartan, rosiglitazone-metformin-
valsartan, and rosiglitazone-metformin-valsartan-ezetimibe
had all decreased oxidative stress in the liver to normal level.
Liver tocopherol/MDA ratio [25], liver MDA level, and liver
PONactivityallwerenotdiﬀerentintheratgroupwhichwas
treated by rosiglitazone-metformin-valsartan-ezetimibe in
comparison with the control rat group. In the rosiglitazone-
metformin-valsartan-ezetimibe ratgroup,serumPONactiv-
ity was normalized, while serum MDA level improved sig-
niﬁcantly, but was still higher compared with the control rat
group. It seems that oxidative stress sources in the serum are
not limited to the liver, but can be from other sources such
as skeletal muscles and adipose tissue. All these medications
have direct or indirect antioxidant eﬀect. In alloxan-induced
type 1diabetes inrats,metformintreatmentledtoadecrease
in plasma lipid peroxidation levels compared to the non-
treated group [37]. Valsartan have been shown to has antiox-
idative eﬀect. Valsartan has phenolic moiety which may con-
tribute to its free radical scavenging capacity [38]. Ezetimibe
can have indirect antioxidative eﬀect on serum LDL [28].
Moreover, in previous report, ezetimibe decreased signiﬁ-
cantly hepatic fat content, triglyceride content, and choles-
terol content by 77%, 53%, and 25%, respectively [25]. Eze-
timibe therapy for 2 years in patients with NAFLD improved
signiﬁcantly steatosis and necroinﬂammatory grades and
ballooning and NAFLD activity scores [39]. Rosiglitazone
exertedasigniﬁcantvascularprotectiveeﬀectinhypercholes-
terolemic rabbits, most likely by attenuation of oxidative and
nitrative stresses [40]. Rosiglitazone decreased O
−
2 produc-
tion when it was incubated together with cadmium or zinc
[41]. Moreover, rosiglitazone upregulates the mRNA and
protein expression of PON2 [42]. Rosiglitazone treatment in
rats with metabolic syndrome decreased hepatic lipid perox-
idation and increased hepatic paraoxonase activity [43].
In parallel with the decreased oxidative stress, PON
activity in the serum was normalized in all treatment groups
andincreasedinrosiglitazonegroup.VanWijketal.reported
that rosiglitazone reduced fasting plasma peroxides and
increased fasting PON-1 activity, without changing PON-
1 mass in type 2 diabetic patients [44]. The only therapy
that normalized the decreased activity of PON in the liver
was rosiglitazone-metformin-valsartan-ezetimibe. Although
PON2 and PON3 mRNA expressions were increased under
treatments with rosiglitazone-metformin, ezetimibe, valsar-
tan, rosiglitazone-metformin-valsartan, and rosiglitazone-
metformin-valsartan-ezetimibe, only in the last group the
PON activity was normalized in the liver. Increased PON2
activity can be due to stabilization of PON2 protein,
increased translational state, or increased mRNA expression.
These diﬀerent mechanisms can explain the diﬀerence
in PON2 activity under diﬀerent treatments beyond the
increased expression of mRNA PON2. The supplementation
of E0 mice with dietary antioxidants signiﬁcantly increased
macrophage PON3 activity, suggesting that oxidative stress
was the cause for the reduced macrophage PON3 activity
[34]. Moreover, PON3 lactonase activity decreases in parallel
to the extent of the oxidative stress. Antioxidants have been
showntopreservePON1activity[35]andpomegranatejuice
and vitamin E have similar eﬀect on E0 mice macrophage
PON3 activity [34]. By pharmacologic intervention, serum
and hepatic oxidative stress was decreased, protecting PON2
and PON3 protein from inactivation leading to increased
serum and liver PON activities. On one side, PON activity
can be increased by antioxidative therapy. On the other
side, it is well documented that both PON2 and PON3
have antioxidant activity. Pretreatment of cultured aortic
endothelial cells with supernatants from HeLa cells over
expressingPON3preventedtheformationofmildlyoxidized
LDL [45]. PON2 overexpression lowers the intracellularInternational Journal of Hepatology 7
oxidative state of HeLa cells treated with hydrogen peroxide
or with oxidized phospholipids [6]. PON2 and PON3
reduced oxidative stress in macrophages from E0 mice [34].
PON1 reduces the content of macrophage lipid peroxides
[46,47].ItseemsthatPON2andPON3mayactaspotentcel-
lular antioxidants [33, 45]. In EA.hy 926 cells, both confocal
microscopyandbiochemicalcellfractionationdemonstrated
a prominent enrichment of PON2 in the nuclear envelope
and the ER. Results were conﬁrmed by microscopy of
overexpressed PON2-iso1-GFP in several other cell types
(SMCs, AoAFs, HeLa, HEK293T, and U2OS) [48]. Experi-
ments performed in 3 major vascular cell types demonstrate
that PON2 is capable of reducing oxidative stress [48]. In
the present study, increased PON2 and PON3 activities
by themselves due to the medications which were used
can further decrease oxidative stress. PON3 mRNA expres-
sion was increased under treatments with rosiglitazone-
metformin, ezetimibe, valsartan, rosiglitazone-metformin-
valsartan, and rosiglitazone-metformin-valsartan-ezetimibe.
With the potential antioxidative stress of these thera-
pies, this can culminate in increased hepatic activity of
PON3.
In the present study, combined therapy with rosiglita-
zone-metformin-valsartan-ezetimibe was the only treatment
that normalized oxidative stress in the liver, decreased oxi-
dative stress in the serum, normalized PON activity both in
the serum and liver by increasing PON2 and PON3 mRNA
expressions and/or due to higher resistance of PON2 and
PON3 protein to inactivation. As previously reported, the
combinedtherapyhadgreatereﬀecttoincreaseinsulinsensi-
tivity and to improve hepatic steatosis than monotherapy in
the MCDD rat model of NAFLD [25].
So it can be deduced that combined therapy by its anti-
oxidative eﬀect and possibly by other direct eﬀects increased
PON2 and PON3 protein activity.
In this experimental model of NAFLD, the increase in
PON2 mRNA levels may be the cell response to oxidative
stress, as was shown for other cellular antioxidant enzymes
[49].
To conclude, increased oxidative stress in experimental
NAFLD decreased PON activity in serum and liver, despite
the increased expression of PON2 mRNA in the liver.
Treatment with insulin sensitizers, ezetimibe, and valsartan
which have antioxidative properties by diﬀerent mechanisms
increased PON2 and PON3 activities which culminated in
normalized oxidative stress both in serum and liver. This
can be due to increased PON2 and PON3 mRNA translation
and/or decreased PON inactivation due to lowered oxidative
stress. Improved histological ﬁndings in these rats as was
shown in previous report [25] can be due, in part, to the
decreased oxidative stress.
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